#2026

As of August 2026, two FDA-approved oral GLP-1 weight-loss pills exist: Foundayo (orforglipron, 12.4% in ATTAIN-1, LillyDirect from $149/mo at 0.8 mg with a dose/refill ladder to $349, no fasting) and the Wegovy pill (semaglutide 25mg, 16.6% in OASIS, NovoCare from $149/mo, dose-dependent, 30-minute pre-dose fast). These were separate trials. Medicare covers both pills at a $50/mo Bridge copay for eligible patients.

GLP-1 medications like Ozempic and Wegovy can help PCOS because the syndrome is driven by insulin resistance, and these drugs improve insulin sensitivity, drive weight loss, and in trials restored menstrual regularity and raised natural-pregnancy rates. But here is the catch almost no one explains: PCOS by itself is NOT an FDA-approved reason to prescribe any GLP-1, so insurance and brand savings cards hinge on your BMI and comorbidities, not your PCOS diagnosis. This guide covers the trial signal, why insurance denies PCOS-only requests, the BMI rules behind savings cards, and the cheaper cash-pay paths if you do not qualify.

IvyRx offers compounded semaglutide from $175/month and tirzepatide from $275/month with a rare flat-rate model, your price never increases as your dose goes up. We reviewed their pricing, clinical oversight, and transparency. Key finding: the flat-rate pricing is genuinely valuable, but IvyRx doesn't publicly disclose a named medical director or their compounding pharmacy partners, which are meaningful gaps for patients who want to verify clinical quality.

Verified May 8, 2026, Updated August 12, 2026: On April 30, FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the list of bulk substances that 503B outsourcing facilities may use based on clinical need. The public comment period closed July 30, 2026 (Docket FDA-2018-N-3240; extension notice 91 FR 38719, published June 26, 2026). Days before that deadline, the Pharmacy Compounding Advisory Committee voted on seven peptides nominated for the separate 503A list and recommended six. Those votes are advisory, not FDA approval, and the 503B proposal was not final when last checked.